Akèy › Limfòm selil-T perifèrik › New York
Etid klinik pou Limfòm selil-T perifèrik nan New York
7 etid pou Limfòm selil-T perifèrik ap chèche patisipan nan sit nan New York.
Vil nan New York
Tèks ofisyèl etid la (Anglè)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07192471Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medicine, New York
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07195916AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, New York
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06137144Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
- New York Medical College, Valhalla
Ap rekriteFaz 1 bonè
Laj 1 a 31 · Tout sèks · Mizajou Aug 18, 2026 · NCT03719105Amping up With PemJAK
- Columbia University Irving Medical Center, New York
Ap rekriteFaz 2
Laj 18 a 95 · Tout sèks · Mizajou Dec 16, 2025 · NCT07283822Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- Columbia University, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2025 · NCT04234048Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.